Michael J. Farrell, an officer and director of ResMed Inc, filed a Form 144 notice of proposed sale of 4,993 shares of ResMed common stock, with an approximate sale date of November 9, 2026, through Fidelity Brokerage Services LLC on NYSE:RMD.

Key Highlights

  • Proposed sale: 4,993 shares of ResMed common stock with an aggregate market value of $1,175,089.20, according to the filing.
  • Acquisition method: The shares were acquired via stock option exercise from the issuer on November 9, 2026, with cash payment on the same date.
  • Shares outstanding: The filing states 140,657,071 shares of ResMed common stock were outstanding at the time of notice.
  • Prior sales disclosed: Farrell sold 4,991 shares on September 8, 2026, for gross proceeds of $1,110,190.55, and 4,991 shares on October 7, 2026, for gross proceeds of $1,129,637.49.
  • 10b5-1 plan: The filing indicates a Rule 10b5-1 trading plan was adopted on October 31, 2024.
  • Broker: Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI 02917, is named as the executing broker.

Farrell's Proposed ResMed Share Sale Under Rule 144

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Michael J. Farrell, who is identified as both an officer and director of ResMed Inc (NYSE:RMD), proposes to sell 4,993 shares of the company's common stock. The filing lists an aggregate market value of $1,175,089.20 for the proposed sale, with an approximate sale date of November 9, 2026. The shares are to be sold on the New York Stock Exchange through Fidelity Brokerage Services LLC.

The filing discloses that the 4,993 shares were acquired through a stock option exercise from the issuer on November 9, 2026, with cash payment made on the same date. ResMed's address of record is listed as 9001 Spectrum Center Blvd., San Diego, California 92123. The notice was signed by Daniel Tucci as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Michael Farrell.

As required under Rule 144, the filing also discloses Farrell's sales of ResMed common stock during the past three months. Those sales consist of 4,991 shares sold on September 8, 2026, generating gross proceeds of $1,110,190.55, and 4,991 shares sold on October 7, 2026, generating gross proceeds of $1,129,637.49. The filing further notes that the Rule 10b5-1 trading plan under which these transactions are conducted was adopted on October 31, 2024.

What Was Disclosed

ResMed officer and director Michael J. Farrell filed a Form 144 notice proposing to sell 4,993 shares of ResMed common stock on November 9, 2026, acquired through a stock option exercise, with the sale to be executed on the NYSE via Fidelity Brokerage Services LLC under a 10b5-1 plan adopted October 31, 2024.